Download Mendeley(3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone: a potent, selective, orally active dipeptidyl peptidase IV inhibitor.
Ammirati, M.J., Andrews, K.M., Boyer, D.D., Brodeur, A.M., Danley, D.E., Doran, S.D., Hulin, B., Liu, S., McPherson, R.K., Orena, S.J., Parker, J.C., Polivkova, J., Qiu, X., Soglia, C.B., Treadway, J.L., VanVolkenburg, M.A., Wilder, D.C., Piotrowski, D.W.(2009) Bioorg Med Chem Lett 19: 1991-1995
- PubMed: 19275964
- DOI: https://doi.org/10.1016/j.bmcl.2009.02.041
- Primary Citation of Related Structures:
3F8S - PubMed Abstract:
A series of 4-substituted proline amides was synthesized and evaluated as inhibitors of dipeptidyl pepdidase IV for the treatment of type 2 diabetes. (3,3-Difluoro-pyrrolidin-1-yl)-[(2S,4S)-(4-(4-pyrimidin-2-yl-piperazin-1-yl)-pyrrolidin-2-yl]-methanone (5) emerged as a potent (IC(50) = 13 nM) and selective compound, with high oral bioavailability in preclinical species and low plasma protein binding. Compound 5, PF-00734200, was selected for development as a potential new treatment for type 2 diabetes.
Organizational Affiliation:
Pfizer Global Research & Development, Groton/New London Laboratories, Pfizer Inc, Groton, CT 06340, United States.
